Related Experiment Videos
Oxcarbazepine and spasticity: further observations
1Unidade de Neurologia Clinica, Hospital Nossa, Senhora das Gracas, Curitiba, Brasil.
Arquivos De Neuro-Psiquiatria
|December 1, 1988
Summary
Oxcarbazepine unexpectedly reduced spasticity in patients with multiple sclerosis and transverse myelitis. This anti-spastic effect occurred at doses below those causing side effects like dizziness.
Area of Science:
- Neurology
- Pharmacology
Background:
- Oxcarbazepine is an antiepileptic drug.
- Spasticity is a common neurological symptom causing muscle stiffness and spasms.
Observation:
- An accidental anti-spastic effect of oxcarbazepine was noted during an antiepileptic drug study.
- Patients with multiple sclerosis and transverse myelitis experienced reduced spasticity.
Findings:
- Oxcarbazepine demonstrated an anti-spastic effect in patients with transverse myelitis and multiple sclerosis.
- The observed effect occurred at daily doses ranging from 600-1200 mg.
- This therapeutic benefit was noted at dosages below the threshold for common side effects such as nausea and dizziness.
Implications:
- Oxcarbazepine may represent a potential therapeutic option for managing spasticity.
- Further research is warranted to confirm and explore the anti-spastic properties of oxcarbazepine.